Metavention develops Metabolic Neuromodulation Therapy (MNT), a transcatheter approach that targets sympathetic nervous system activity to improve glucose control in Type 2 diabetes and potentially abnormal liver function. MNT uses standard interventional vascular techniques to modulate overactive sympathetic nerves with the aim of lowering blood glucose and improving metabolic outcomes. The company announced a $65 million Series C and will use the funds to optimize its MNT therapy and commence preparations for a Phase 2 study in the United States. In conjunction with the financing Metavention appointed Todd Berg as Chief Executive Officer; Berg previously served as CEO of Torax Medical, which was acquired by Ethicon (Johnson & Johnson) in 2017. The leadership team also includes founder, president and chief medical officer Bobak Azamian, M.D., Ph.D. Metavention is headquartered in Minneapolis, Minn.

Total raised

$65M

Funding rounds

1

Latest round

Series C

Latest activity

Jan 2018